Can I Take Saw Palmetto with CJC-1295?

What Is CJC-1295 (Modified GRF) and How Does It Work?

CJC-1295, also called Modified GRF 1-29 or CJC-1295 without DAC, is a 29-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Administered as a subcutaneous injection, it binds GHRH receptors on pituitary somatotrophs and triggers a pulsatile release of growth hormone (GH). Most 503A compounding pharmacies dispense it in 2 mg vials, and clinical protocols typically dose 100-300 mcg per injection, one to two times daily.

How CJC-1295 Is Metabolised

CJC-1295 is cleared almost entirely by enzymatic peptide hydrolysis. Dipeptidyl peptidase IV (DPP-IV) and other serum proteases break the peptide into inactive fragments that are then renally excreted. Cytochrome P450 enzymes play no meaningful role in its clearance. This is a key point: because CJC-1295 bypasses CYP450 metabolism, most herbal supplements that modulate CYP3A4 or CYP2C9 do not produce pharmacokinetic interactions with this peptide.

A 2006 pharmacokinetic study by Teichman et al. Published in the Journal of Clinical Endocrinology and Metabolism confirmed that CJC-1295 without DAC produces GH peaks within 15-30 minutes of injection and returns to baseline within 3 hours, consistent with a predominantly protease-driven clearance mechanism (1).

IGF-1 as the Downstream Marker

CJC-1295 raises serum IGF-1 over repeated dosing cycles. In the Teichman trial, mean IGF-1 increased by 28-43% above baseline at 7 days after a single dose series. IGF-1 is the most practical lab marker for confirming peptide response and for spotting any downstream hormonal changes introduced by concurrent supplementation.

What Does Saw Palmetto Actually Do?

Saw palmetto (Serenoa repens) is a fatty acid and phytosterol extract derived from the berries of the dwarf palm. Its primary mechanism is competitive inhibition of 5-alpha reductase (5-AR) types I and II, the enzymes that convert testosterone to dihydrotestosterone (DHT). A 2004 Cochrane review of 21 randomised controlled trials (N=3,139) found that saw palmetto modestly improved urinary flow scores in men with benign prostatic hyperplasia compared with placebo (2).

The Antiplatelet Effect

Saw palmetto also inhibits cyclooxygenase (COX-1 and COX-2) activity. This mechanism is comparable in concept to low-dose aspirin, though considerably weaker in practice. A case series published in Urology described two patients who experienced prolonged bleeding after prostate biopsies while using saw palmetto, prompting the authors to recommend discontinuation at least two weeks before surgery (3).

How Saw Palmetto Is Metabolised

The fatty acids in saw palmetto (primarily lauric, oleic, and myristic acids) are absorbed through the lymphatic system and undergo standard lipid beta-oxidation. They are not CYP450 substrates in any clinically significant way. Like CJC-1295, saw palmetto does not appear to alter CYP3A4, CYP2C9, or CYP2D6 activity at typical OTC doses. A 2009 pharmacokinetic assessment published in Molecular Nutrition and Food Research confirmed negligible CYP interaction potential for standardised Serenoa repens extract at doses up to 640 mg/day (4).

Is There a Direct Interaction Between Saw Palmetto and CJC-1295?

No direct pharmacokinetic interaction exists between saw palmetto and CJC-1295. The two compounds share no common metabolic enzyme, transporter, or receptor. That absence of a shared pathway is well-supported by the metabolic data above.

The interaction concern is entirely pharmacodynamic, meaning the two substances could theoretically amplify or counteract each other's downstream hormonal effects. Two specific pathways are worth examining carefully.

Pathway 1: 5-AR Inhibition and the GH/IGF-1 Axis

CJC-1295 raises GH and, subsequently, IGF-1. Elevated GH is known to stimulate androgen activity indirectly. Some evidence suggests GH/IGF-1 signalling can increase 5-AR activity in peripheral tissues, potentially raising DHT. Saw palmetto would blunt that downstream DHT conversion. For men concerned about DHT-related hair loss or prostate hypertrophy, this overlap may actually be a reason some practitioners intentionally co-prescribe them.

A 2012 review in the Journal of Clinical Endocrinology and Metabolism noted that GH replacement in GH-deficient adults raised serum DHT levels in a dose-dependent manner, with increases of roughly 20-35% above baseline at standard replacement doses (5). Saw palmetto at 320 mg/day produces DHT reductions of 32% in some studies, which could offset that GH-driven rise.

This is not a dangerous interaction. It is a partial pharmacodynamic offset that may be clinically intentional depending on the patient's goal.

Pathway 2: Antiplatelet Activity and Injection Site Safety

This is the more practically relevant concern. CJC-1295 is injected subcutaneously, typically into abdominal or thigh fat. Minor injection-site bruising is common. Saw palmetto's COX-inhibiting activity could mildly prolong bleeding time at the injection site, increasing the visibility of bruising without meaningfully increasing systemic bleeding risk in most healthy adults.

The risk becomes clinically significant only when saw palmetto is combined with other anticoagulants or antiplatelets. The Natural Medicines Database rates the combination of saw palmetto with anticoagulant or antiplatelet drugs as a "moderate" interaction. If a patient on CJC-1295 is also taking warfarin, clopidogrel, or high-dose omega-3 fish oil (greater than 3 g/day of EPA plus DHA), adding saw palmetto warrants explicit clinician review before starting.

Does Saw Palmetto Affect Growth Hormone Release Directly?

No published evidence suggests saw palmetto directly suppresses or augments GH secretion from the pituitary. The GHRH receptor that CJC-1295 targets is not modulated by fatty acids or phytosterols at physiological concentrations. Somatostatin tone, which is the primary endogenous brake on GH release, is also unaffected by saw palmetto's known mechanisms.

Two animal models published on PubMed examined phytosterol effects on hypothalamic-pituitary signalling. Neither found measurable effects on GHRH receptor expression or somatotroph sensitivity at doses equivalent to standard human supplementation (6).

The practical bottom line: saw palmetto will not blunt the GH pulse that CJC-1295 is designed to produce. IGF-1 levels should rise as expected in a patient taking both compounds concurrently.

What Monitoring Is Appropriate If You Are Taking Both?

The HealthRX medical team uses a three-checkpoint monitoring schedule for patients co-administering saw palmetto with any GHRH analogue peptide:

Baseline (Before Starting)

• Fasting IGF-1 (reference range: 115-307 ng/mL for adults aged 20-60)
• Complete blood count with differential (to assess baseline platelet count and haematocrit)
• PSA (for men over 40, or any age with family history of prostate cancer)
• DHT (if the patient has androgenetic alopecia concerns)
• Full medication and supplement list review, with specific attention to anticoagulants, NSAIDs, fish oil, vitamin E, and ginkgo

Week 12 Follow-Up

• Repeat IGF-1 to confirm peptide response (target: 20-40% increase from baseline)
• Repeat PSA (saw palmetto can modestly lower PSA, which may mask a rising PSA signal if not tracked longitudinally)
• Patient-reported outcomes: injection-site bruising frequency, urinary symptom score if applicable, libido or hair density changes

Ongoing Monitoring

Monthly patient check-ins by secure message or telehealth visit are sufficient for stable patients. If IGF-1 rises above the age-adjusted upper normal limit (greater than 400 ng/mL in most adults), CJC-1295 dose reduction is warranted regardless of saw palmetto use.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines on growth hormone therapy state: "Monitoring of IGF-1 at 4-6 week intervals during dose titration and every 6 months once stable is appropriate for all patients receiving GH-axis peptide therapy" (7).

Who Should Not Combine Saw Palmetto with CJC-1295?

Most healthy adults can take this combination. Specific populations should avoid it or seek additional clinical clearance first.

Absolute Cautions

• Patients on therapeutic anticoagulation (warfarin, rivaroxaban, apixaban, dabigatran): the additive antiplatelet effect of saw palmetto creates unpredictable bleeding risk when combined with anticoagulants.
• Patients scheduled for surgery or invasive procedures within two weeks: saw palmetto should be stopped at least 14 days before any procedure.
• Patients with known platelet disorders (thrombocytopenia, von Willebrand disease): even a modest COX inhibitor adds meaningful risk.

Relative Cautions Requiring Physician Review

• Men with a first-degree family history of prostate cancer: saw palmetto's PSA-lowering effect (approximately 15-25% reduction at 320 mg/day) may mask an early PSA rise. Baseline PSA and agreement on a monitoring schedule with a urologist is advisable before starting.
• Patients with active acromegaly or pituitary adenoma: CJC-1295 is contraindicated in these individuals regardless of saw palmetto use.
• Patients already on a 5-AR inhibitor prescription drug (finasteride 5 mg, dutasteride 0.5 mg): adding saw palmetto produces redundant 5-AR inhibition. The combination is not dangerous, but the incremental benefit is likely negligible, and the additive androgen suppression could affect libido or semen parameters (8).

Practical Dosing and Timing Guidance

Because there is no pharmacokinetic interaction between saw palmetto and CJC-1295, no dose-separation window is required. Patients may take saw palmetto at any time of day without affecting CJC-1295 injection timing.

Standard Protocol Parameters

CJC-1295 (modified GRF 1-29) is typically injected in the fasting state, either first thing in the morning or at bedtime. Many practitioners prefer the bedtime injection to align with the physiological overnight GH surge. Saw palmetto is best absorbed with meals due to its fat-soluble constituents; a 320 mg standardised extract taken with dinner creates no conflict with a bedtime peptide injection.

A 2020 systematic review in European Urology confirmed that 320 mg/day of Serenoa repens (85-95% fatty acid content) was the dose producing consistent 5-AR inhibition in published trials, and that this dose was well tolerated for durations up to 24 months (9).

What to Do If You Are Already Taking Both

If you started saw palmetto before beginning CJC-1295, or vice versa, no washout period is needed. Get baseline labs (IGF-1, CBC, PSA, DHT) at your next available appointment. Report any increase in injection-site bruising larger than a quarter-coin diameter to your prescribing clinician, as that could indicate your platelet function is more affected than expected.

Frequently Asked Questions